|
||||||||||||||||||||||
|
|
Phase II Chemotherapy with Chromomycin for Advanced Multiple Myeloma
Basic Trial Information
Objectives I. Determine the effectiveness of chromomycin for advanced multiple myeloma. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with multiple myeloma who are resistant to drugs of greater proven efficacy, and not eligible for studies of higher priority. Expected Enrollment Protocol closed 06/76. Protocol terminated 06/77. Outline Nonrandomized study. Single-Agent Chemotherapy. Chromomycin, CHR, NSC-58514. Trial Lead Organizations Southwest Oncology Group
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |